🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🎥 Sometimes, complete cytoreduction for #LAMN calls for bold moves - like this one, vibrantly featured by Surgical Oncology Research at Mercy team in Annals of Surgical Oncology 👩‍⚕️🧑‍⚕️ 🔪🔥 Your weekend CRS-#HIPEC must-watch: doi.org/10.1245/s10434… Vadim Gushchin, MD, FACS Mary Caitlin King Sergei Iugai, MD Armando Sardi, MD, FACS

P-values rule research, but do they answer our questions? Review IASO-IJSO online compares frequentist vs. Bayesian meta-analysis. Tata Memorial Hospital ACTREC-TMC Cancer Research Institute - ACTREC @ACPGBI European Society of Coloproctology Young ESCP ASCRS_1 Peritoneal Surface Oncology Group International INDEPSO BJS SoMe4Surgery

Distinct gene signatures define the epithelial cell features of mucinous appendiceal neoplasms and pseudomyxoma metastases frontiersin.org/journals/genet…

#CAIRO6 Abstract available now ! "Among patients with resectable colorectal peritoneal metastases, perioperative systemic therapy did not result in superior overall survival as compared to CRS- HIPEC alone " Watch out for the presentation on the 30th May @ the ASCO annual

#ASCO2025 Continuing on KRASG12C in CRC Olomorasib (second gen KRAS G12C) + Cetuximab in previously treated KRAS G12C CRC 49 patients in dose expansion, 44 in optimization phase ORR 42% mPFS 7.5 months AEs 24% > G3 1/3 of patients remain on treatment Second gen KRASG12C...

#ASCO2025 📢Practice changing for Biliary Tract and Gallbladder Cancers! GAIN trial Neoadjuvant chemo drastically improves outcomes in resectable BTC/GBC Phase III, randomized (N=68, stopped early due to accrual) Arm A: Gem/Cis ×3 → surgery → Gem/Cis ×3 Arm B: surgery →

Periop chemo provides superior PFS. Half the progression rate….. both ITT OS and PP OS show good hazards ratios, but underpowered to prove it. Interpretation: should probably give periop chemo.

#PSOGI2025 #PSOGIBarcelona Final call: abstract submission deadline approaching!  📅 June 1st at ⏲️ 23:59 (CET). The time is now. You may choose to present your work in ✳️ oral, poster, or video format ✳️ select from a wide range of scientific topics (peritoneal

Perfect interpretation! Completely agree. The benefit of adjuvant chemo is 6-8%. Perhaps 15% is an overestimation?

Final Call for Peritoneal Surface Oncology Group International 2025 Abstract Submissions is by June 1 oncodaily.com/blog/psogi-300… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #PSOGI #PSOGI2025 #PSOGIBarcelona #Abstract CancerWorld

Much later than we expected, here’s a snapshot of our wonderful PMP patients proudly wearing their free sweatshirts from us. We are sure you’ll agree that everyone looks fantastic in them! #raisingawarenesstogether #pseudomyxomasurvivor #pseudomyxomaperitonei #appendixcancer

Bhaktapur Cancer Hospital launched Nepal’s first PSM program on October 2023; first HIPEC being performed on 1st Oct 2023, and is organizing a CME to raise awareness. Join us to learn more and share your experiences. ISSPP Peritoneal Surface Oncology Group International OncoDaily INDEPSO SingHealth

📢 Save the Date! 🎓 You are invited to the Peritoneal Surface Malignancy Course organized by Turkish Society of Colon and Rectal Surgery (TSCRS) and PSOGI! 🗓 July 11–12, 2025 🔹 Day 1: Live Surgery, Simultaneous Video Discussions, Hands-On Sessions 🔹 Day 2: Video-Based

Dr. de Hingh w/ CAIRO6, Perioperative systemic therapy for resectable CRC peritoneal metastases. 6 months peri-op tx. 3 year OS 54 vs 53%. PFS HR 0.51 (3 year PFS 20 vs 4%). #ASCO25

#ASCO25 1️⃣st relevant study 📚from a surgical🔪multi-disciplinary standpoint. CAIRO-6 Cytoreductive Surgery (CRS)+HIPEC in patients with PERITONEAL metastases ➕/➖ Systemic peri-operative My🔑take is 45-54 months OS 👀. Highest to date in peritoneal Mets. OncoAlert #CRCSM

Perioperative systemic therapy for resectable colorectal peritoneal metastases #ASCO25 🔎 CAIRO-6 phs 3 trial 👉mPFS 14 vs 7 mo 👉mDFs 12 vs 7 mo 👉mOS 44 vs 39 mo 🧐 No OS benefit in IIT, but better OS in synchronous right-sided tumors ESMO - Eur. Oncology

CAIRO6: Will CRS/HIPEC ⬆️ OS vs chemo alone in #colorectalcancer #peritoneal mets? 🔴 Did not meet endpoint for OS 🔴 OS of 54M vs 45M (NS) 🔵 PFS of 14M vs 7M 🔵 Median F/U of 41M #cancer #cancerresearch

Highest OS in a RCT. Similar overall survival reported in several retrospective studies with CRS+HIPEC +systemic chemo Pashtoon Kasi MD, MS pubmed.ncbi.nlm.nih.gov/36729351/

It’s not CRS + HIPEC versus systemic chemo It’s CRS + HIPEC versus CRS+ HIPEC+ Systemic chemo